Phase I trial of bi-weekly paclitaxel and gemcitabine as second-line therapy for patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy

Medical Oncology

Volumn 21, Issue 2, 2004, Pages 133-138

  Koizumi, Tomonobu ^a   Yoshiike, Fumiaki ^a   Inou, Hitoshi ^a   Hatayama, Orie ^a   Sasabayashi, Mari ^a   Tsushima, Kenji ^a   Yamamoto, Hiroshi ^a   Hayasaka, Muneharu ^a   Kubo, Keishi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bi weekly chemotherapy; Neurotoxicity; Non small cell lung cancer; Platinum resistant; Second line chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; GEMCITABINE; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SCREENING; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; INFECTION; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PACLITAXEL;

EID: 4243167900     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:21:2:133     Document Type: Article

References (28)

1. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta analysis using updated data on indiviual patients from 52 randomised clinical trials. Br Med J 1995; 31:899-909.
2. American Society of Clinical Oncology. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997; 15:2996-3018.
3. Schiller JH, et al. For the Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Eng J Med 2002; 346(2): 92-98.
4. Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998; 4:1087-1100.
5. Huisman C, Smit EF, Giaccone G, Postmus PE. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol 2000; 18:3722-3730.
6. Fossella FV, Lynch T, Shepherd FA. Second line chemotherapy for NSCLC: establishing a gold standard. Lung Cancer 2002; 38:S5-S12.
7. Rowinsky EK, Donehower RC. The clinical pharmacology of paclitaxel (Taxol). Semin Oncol 1993; 20:16-25.
8. Hertel LW, et al. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluorodeoxycytidine). Cancer Res 1990; 50:4417-4422.
9. Murphy WK, et al. Phase II study of Taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 1993; 85:384-388.
10. Abratt RP, et al. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994; 12:1535-1540.
11. Sandler AB, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18:122-130.
12. Hainsworth JD, et al. One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer; results of a multicentre. Phase II trial. Eur J Cancer 1997; 34:654-658.
13. Langer CJ, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: a phase II toxicity, response and survival analysis. J Clin Oncol 1995; 13:1360-1370.
14. Kroep JR, et al. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 1999; 17:2190-2197.
15. Rothenberg ML, et al. Phase I trial of paclitaxel and gemeitabine administered, every two weeks in patients with refractory solid tumors. Ann Oncol 1998; 9:733-738.
16. Isla D, et al. Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2001; 19:1071-1077.
17. Gelmon KA, et al. Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. J Clin Oncol 1996; 14:1185-1191.
18. Koizumi T, et al. Phase I trial of weekly docetaxel combined with cisplatin in patients with non-small-cell lung cancer. Lung Cancer 2001; 34:125-131.
19. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-214.
20. Depas T, et al. Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in cheo-naïve patients with advanced non-small-cell lung cancer. Ann Oncol 2000; 11:821-827.
21. Postma TJ, Hockman K, van Kiel JMGH, Heimans JJ, Vermorken JB. Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer. J Neuro-Oncol 1999; 45:241-246.
22. Schwartz GN, et al. The clinical development of paclitaxel and the paclitaxel/carboplatin combination. Eur J Cancer 1998; 34:1543-1548.
23. Connelly E, et al. Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers; unexpected incidence of neurotoxocity. Gynecol Oncl 1996; 62:166-168.
24. Eisenhauer EA, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994; 12:2654-2666.
25. Greco FA, Thomas M, Hainsworth JD. One-hour paclitaxel infusions: review of safety and efficacy. Cancer J Sci Am 1999; 5:179-191.
26. Hainsworth JD, Greco FA. Paclitaxel administered by 1-hour infusion. Preliminary results of a phase I/II comparing two schedules. Cancer 1994; 74:1377-1382.
27. Mross K, et al. Clinical phase I study with one-hour paclitaxel infusion. Ann Oncol 1998; 9:569-572.
28. Fossella FV, et al. Randomized phase III trail of docetaxel versus vinorelbine or ifofamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000; 18:2354-2362.